US Stock MarketDetailed Quotes

TVGN Tevogen Bio Holdings

Watchlist
  • 1.040
  • -0.020-1.92%
Trading Mar 11 12:18 ET
181.98MMarket Cap-13.00P/E (TTM)

About Tevogen Bio Holdings Company

Tevogen Bio Holdings, Inc. is a clinical-stage specialty immunotherapy company. It develops off-the-shelf therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company was founded on February 14, 2024 and is headquartered in Warren, NJ.

Company Profile

SymbolTVGN
Company NameTevogen Bio Holdings
Listing DateJan 3, 2022
CEODr. Ryan Saadi, M.D.,M.P.H.
MarketNASDAQ
Employees17
Fiscal Year Ends12-31
Address15 Independence Boulevard,Suite 410
CityWarren
ProvinceNew Jersey
CountryUnited States of America
Zip Code07059
Phone1-877-838-6436

Company Executives

  • Name
  • Position
  • Salary
  • Dr. Ryan Saadi, M.D.,M.P.H.
  • Chairman of the Board and Chief Executive Officer
  • 501.00K
  • Kirti Desai
  • Chief Financial Officer
  • 300.00K
  • Dr. Neal Flomenberg, M.D.
  • Chief Scientific Officer and Global Research and Development Lead
  • 2.93M
  • Sadiq Khan
  • Chief Commercial Officer
  • --
  • Victor Sordillo
  • Director
  • 253.46K
  • Dr. Keow Lin Goh
  • Director
  • --
  • Susan M. Podlogar
  • Director
  • --
  • Jeffrey Feike
  • Director
  • --
  • Dr. Curtis Patton
  • Director
  • --

Trending Stocks

Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries

Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.

Unlock Now
Discussing
Tesla's earnings caused fluctuations, what's your market outlook?
Tesla's Q4 2024 revenue was $25.71 billion, up 2% year-on-year but below expectations. Can Tesla's stock price keep rising in 2025 with Trum Show More